Zobrazeno 1 - 10
of 117
pro vyhledávání: '"A. A. Mesnyankina"'
Publikováno v:
Современная ревматология, Vol 16, Iss 1, Pp 77-83 (2022)
Glucocorticoids (GC) currently remain one of the most important components of the treatment of systemic lupus erythematosus (SLE). However, prolonged use of GC inevitably leads to the development of irreversible organ damage. It has been proven that
Externí odkaz:
https://doaj.org/article/bdc566f244a14a639b0e6d27bdc8c8af
Autor:
N. Yu. Nikishina, E. V. Ermolaeva, A. A. Mesnyankina, E. A. Aseeva, S. K. Soloviev, B. Sh. Isaeva, G. M. Koylubaeva, A. M. Lila
Publikováno v:
Современная ревматология, Vol 15, Iss 6, Pp 111-116 (2021)
Systemic lupus erythematosus (SLE) is a multisystem disease characterized by chronic inflammation and damage to vital organs and systems. Despite the great success achieved in the treatment of SLE, glucocorticoids (GC) remain one of the main methods
Externí odkaz:
https://doaj.org/article/c4d317a0adbd47aa8a0bf24ee80cd796
Autor:
E. A. Aseeva, N. Yu. Nikishina, A. A. Mesnyankina, S. K. Solovyev, B. Sh. Isaeva, G. M. Koilubaeva, A. M. Lila
Publikováno v:
Современная ревматология, Vol 15, Iss 3, Pp 98-102 (2021)
The development of irreversible organ damage (IOD) in systemic lupus erythematosus (SLE) significantly increases the risk of death, worsens the quality of life and significantly increases the cost of treatment. The development and implementation of s
Externí odkaz:
https://doaj.org/article/8e3e45cfa6b145e08307eb7c6180b211
Autor:
N. L. Kozlovskaya, S. K. Solovyev, E. A. Aseeva, T. V. Popkova, T. A. Panafidina, E. L. Nasonov, A. M. Lila, A. A. Mesnyankina, N. Yu. Nikishina
Publikováno v:
Современная ревматология, Vol 15, Iss 1, Pp 9-14 (2021)
The paper presents the main provisions of the updated 2019 EULAR/ERA-EDTA guidelines for the lupus nephritis (LN) therapy, which have been prepared by an international group of rheumatologists, nephrologists, morphologists, and pediatricians. Part 2
Externí odkaz:
https://doaj.org/article/ad037bdef3f84450bdb0d2dfadb97703
Autor:
N. L. Kozlovskaya, S. K. Solovyev, E. A. Aseeva, T. V. Popkova, T. A. Panafidina, E. L. Nasonov, A. M. Lila, A. A. Mesnyankina, N. Yu. Nikishina
Publikováno v:
Современная ревматология, Vol 14, Iss 4, Pp 7-15 (2020)
The paper presents the main provisions of the 2019 updated European League Against Rheumatism (EULAR)/European Renal Association (ERA) – European Dialysis and Transplant Association (EDTA) guidelines for the management of lupus nephritis. It discus
Externí odkaz:
https://doaj.org/article/282aaa188cb3413cbbfe9a1da968d5ed
Autor:
A. A. Mesnyankina, S. K. Solovyev, N. Yu. Nikishina, E. A. Aseeva, N. V. Demidova, E. L. Nasonov
Publikováno v:
Современная ревматология, Vol 14, Iss 4, Pp 31-38 (2020)
Objective: to determine the efficiency of sequential (combined) therapy with rituximab (RTM) and belimumab (BLM) in patients with active systemic lupus erythematosus (SLE).Patients and methods. Twelve patients with true SLE having moderate-to-high ac
Externí odkaz:
https://doaj.org/article/a593fe674bd241b8a837f49274f137fe
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 92-95 (2019)
Review of literature on the analysis of current data on the efficacy of belimumab (BLM) in systemic lupus erythematosus (SLE). It provides data on the high efficacy of BLM in high and medium activity of SLE in patients with joints damage, skin lesion
Externí odkaz:
https://doaj.org/article/eb8609aa61844d098cb99eba202ca595
Publikováno v:
Научно-практическая ревматология, Vol 57, Iss 2, Pp 191-196 (2019)
Recommendations for the management of patients with systemic lupus erythematosus (SLE) in real clinical practice are presented. They take into account the course, activity, damage, and consider assessment of these parameters with validated indices. T
Externí odkaz:
https://doaj.org/article/11f96e26b045414d8f8ace30bc6d2f25
Autor:
A. A. Mesnyankina, S. K. Solovyev, E. A. Aseeva, A. P. Aleksankin, E. N. Aleksandrova, E. L. Nasonov
Publikováno v:
Современная ревматология, Vol 13, Iss 1, Pp 35-43 (2019)
Objective: to evaluate the effect of different biological agents (BAs), including rituximab (RTM) and belimumab (BLM) combination therapy, on B-lymphocyte subpopulations during a follow-up of patients with systemic lupus erythematosus (SLE).Patients
Externí odkaz:
https://doaj.org/article/5fddb8487ffd492c9c81448d174933e5
Publikováno v:
Научно-практическая ревматология, Vol 56, Iss 3, Pp 302-309 (2018)
Objective: to investigate the effect of various biological agents (BAs), including combined treatment with rituximab (RTM) and belimumab (BLM), on the activity of systemic lupus erythematosus (SLE) and to evaluate their efficacy and impact on some pa
Externí odkaz:
https://doaj.org/article/ccc47f2c29bc4e7183223335d97da173